Bone and joint neuropathy in rats with type-2 diabetes

Regulatory Peptides

Volumn 119, Issue 1-2, 2004, Pages 61-67

  Ahmad, Tashfeen ^a,b   Ugarph Morawski, Anna ^b   Li, Jian ^a   Bileviciute Ljungar, Indre ^a   Finn, Anja ^a   Östenson, Claes Göran ^b   Kreicbergs, Andris ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcitonin gene related peptide; Diabetic neuropathy; Diabetic osteopathy; Goto Kakizaki rat; Neuropeptide Y; Neuropeptides; Substance P

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROPEPTIDE Y; SUBSTANCE P;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE DISEASE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; IMMUNOHISTOCHEMISTRY; JOINT; LUMBAR SPINAL CORD; MEGAKARYOCYTE; NERVE FIBER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEPTIDE ANALYSIS; PERIOSTEUM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SPINAL GANGLION; SYNOVIUM;

ANIMALS; BONE AND BONES; BONE MARROW; CALCITONIN GENE-RELATED PEPTIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GANGLIA, SPINAL; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; JOINTS; NEUROPEPTIDE Y; NEUROPEPTIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; SUBSTANCE P;

RATTUS NORVEGICUS;

EID: 1842785714     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2003.12.008     Document Type: Article

References (54)

1. Aubert R.E., Ballard D.J., Bennett P.H., Barrett-Connor E. Diabetes in America. 2nd ed. 1995;DIANE Publishing, Collingdale, PA. http://diabetes.niddk. nih.gov/dm/pubs/america/contents.htm.
2. Fernyhough P., Diemel L.T., Brewster W.J., Tomlinson D.R. Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor messenger RNA in streptozotocin-diabetic rats: effects of insulin treatment. Neuroscience. 62(2):1994;337-344.
3. Levy D.M., Karanth S.S., Springall D.R., Polak J.M. Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: an immunocytochemical study. Diabetologia. 32(7):1989;427-433.
4. Robinson J.P., Willars G.B., Tomlinson D.R., Keen P. Axonal transport and tissue contents of substance P in rats with long-term streptozotocin-diabetes. Effects of the aldose reductase inhibitor 'statil'. Brain Res. 426(2):1987;339-348.
5. Murakawa Y., Zhang W., Pierson C.R., Brismar T., Ostenson C.G., Efendic S.et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab. Res. Rev. 18(6):2002;473-483.
6. Vogt M.T., Cauley J.A., Tomaino M.M., Stone K., Williams J.R., Herndon J.H. Distal radius fractures in older women: a 10-year follow-up study of descriptive characteristics and risk factors. The study of osteoporotic fractures. J. Am. Geriatr. Soc. 50(1):2002;97-103.
7. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., Schreiner P.J.et al. Older women with diabetes have an increased risk of fracture: a prospective study. J. Clin. Endocrinol. Metab. 86(1):2001;32-38.
8. Jeffcoate W., Lima J., Nobrega L. The Charcot foot. Diabet. Med. 17(4):2000;253-258.
9. Tuominen J.T., Impivaara O., Puukka P., Ronnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 22(7):1999;1196- 1200.
10. Buysschaert M., Cauwe F., Jamart J., Brichant C., De Coster P., Magnan A.et al. Proximal femur density in type 1 and 2 diabetic patients. Diabetes Metab. 18(1):1992;32-37.
11. Bouillon R. Diabetic bone disease. Calcif. Tissue Int. 49(3):1991;155-160.
12. Ahmad T., Ohlsson C., Sääf M., Ostenson C.G., Kreicbergs A. Skeletal changes in type-2 diabetic Goto-Kakizaki rats. J. Endocrinol. 178(1):2003;111-116.
13. Wittenberg R.H., Peschke U., Bötel U. Heterotopic ossification after spinal cord injury. Epidemiology and risk factors. J. Bone Joint Surg. Br. 74(2):1992;215-218.
14. Mendelson L., Grosswasser Z., Najenson T., Sandbank U., Solzi P. Periarticular new bone formation in patients suffering from severe head injuries. Scand. J. Rehabil. Med. 7(4):1975;141-145.
15. Cundy T.F., Edmonds M.E., Watkins P.J. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet. Med. 2(6):1985;461-464.
16. Carpintero P., Logroño C., Carreto A., Carrascal A., Lluch C. Progression of bone lesions in cured leprosy patients. Acta Leprol. 11(1):1998;21-24.
17. Goto Y., Kakizaki M., Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J. Exp. Med. 119(1):1976;85-90.
18. Ostenson C.G. The Goto-Kakizaki rat. Sima A.A.F., Shafrir E. Animal models in diabetes: a primer (Frontiers in Animal Diabetes Research). 2001;197-211 Harwood Academic Publishers, Amsterdam.
19. Ostenson C.G., Fière V., Ahmed M., Lindström P., Brismar K., Brismar T.et al. Decreased cortical bone thickness in spontaneously non-insulin-dependent diabetic GK rats. J. Diabetes Complications. 11(6):1997;319-322.
20. Zamboni L., De Martino C. Buffered picric acid-formaldehyde: a new, rapid fixative for electron microscopy. J. Cell Biol. 35:1967;148.
21. Bjurholm A., Kreicbergs A., Schultzberg M. Fixation and demineralization of bone tissue for immunohistochemical staining of neuropeptides. Calcif. Tissue Int. 45(4):1989;227-231.
22. Ahmed M., Bjurholm A., Srinivasan G.R., Theodorsson E., Kreicbergs A. Extraction of neuropeptides from joint tissue for quantitation by radioimmunoassay. A study in the rat. Peptides. 15(2):1994;317-322.
23. Meyer M.F., Rose C.J., Hülsmann J.O., Schatz H., Pfohl M. Impaired 0.1-Hz vasomotion assessed by laser Doppler anemometry as an early index of peripheral sympathetic neuropathy in diabetes. Microvasc. Res. 65(2):2003;88-95.
24. Cacciatori V., Dellera A., Bellavere F., Bongiovanni L.G., Teatini F., Gemma M.L.et al. Comparative assessment of peripheral sympathetic function by postural vasoconstriction arteriolar reflex and sympathetic skin response in NIDDM patients. Am. J. Med. 102(4):1997;365-370.
25. Ahmad T., Ohlsson C., Ostenson C.G., Kreicbergs A. Peripheral quantitative computed tomography for the detection of diabetic osteopathy. A study in the Goto-Kakizaki rat. Invest. Radiol. 38(3):2003;171-176.
26. Kreicbergs A., Ahmed M. Neuropeptides in bone. Curr. Opin. Orthop. 8(V):1997;71-79.
27. Lerner U.H. Neuropeptidergic regulation of bone resorption and bone formation. J. Musculoskelet. Neuronal Interact. 2(5):2002;440-447.
28. Rix M., Andreassen H., Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care. 22(5):1999;827-831.
29. Bjurholm A. Neuroendocrine peptides in bone. Int. Orthop. 15(4):1991;325-329.
30. Mori T., Ogata T., Okumura H., Shibata T., Nakamura Y., Kataoka K. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochem. Biophys. Res. Commun. 262(2):1999;418-422.
31. Sherman B.E., Chole R.A. A mechanism for sympathectomy-induced bone resorption in the middle ear. Otolaryngol. Head Neck Surg. 113(5):1995;569-581.
32. Goto T., Yamaza T., Kido M.A., Tanaka T. Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone. Cell Tissue Res. 293(1):1998;87-93.
33. Zaidi M., Alam A.S., Bax B.E., Shankar V.S., Bax C.M., Gill J.S.et al. Role of the endothelial cell in osteoclast control: new perspectives. Bone. 14(2):1993;97-102.
34. Cornish J., Callon K.E., Bava U., Kamona S.A., Cooper G.J., Reid I.R. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone. 29(2):2001;162-168.
35. Cornish J., Callon K.E., Lin C.Q., Xiao C.L., Gamble G.D., Cooper G.J.et al. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J. Bone Miner. Res. 14(8):1999;1302-1309.
36. Garrett N.E., Malcangio M., Dewhurst M., Tomlinson D.R. Alpha-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci. Lett. 222(3):1997;191-194.
37. Karanth S.S., Springall D.R., Francavilla S., Mirrlees D.J., Polak J.M. Early increase in CGRP- and VIP-immunoreactive nerves in the skin of streptozotocin-induced diabetic rats. Histochemistry. 94(6):1990;659-666.
38. Willars G.B., Calcutt N.A., Compton A.M., Tomlinson D.R., Keen P. Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. Effects of aldose reductase inhibition. J. Neurol. Sci. 91(1-2):1989;153-164.
39. Wallengren J., Badendick K., Sundler F., Håkanson R., Zander E. Innervation of the skin of the forearm in diabetic patients: relation to nerve function. Acta Derm.-Venereol. (Stockh.). 75(1):1995;37-42.
40. Ericsson A., Schalling M., McIntyre K.R., Lundberg J.M., Larhammar D., Seroogy K.et al. Detection of neuropeptide Y and its mRNA in megakaryocytes: enhanced levels in certain autoimmune mice. Proc. Natl. Acad. Sci. U. S. A. 84(16):1987;5585-5589.
41. Lindblad B.E., Nielsen L.B., Jespersen S.M., Bjurholm A., Bunger C., Hansen E.S. Vasoconstrictive action of neuropeptide Y in bone. The porcine tibia perfused in vivo. Acta Orthop. Scand. 65(6):1994;629-634.
42. Gross T.S., Damji A.A., Judex S., Bray R.C., Zernicke R.F. Bone hyperemia precedes disuse-induced intracortical bone resorption. J. Appl. Physiol. 86(1):1999;230-235.
43. Laroche M. Intraosseous circulation from physiology to disease. Joint Bone Spine. 69(3):2002;262-269.
44. Edmonds M.E., Roberts V.C., Watkins P.J. Blood flow in the diabetic neuropathic foot. Diabetologia. 22(1):1982;9-15.
45. Hohmann E.L., Levine L., Tashjian A.H. Jr. Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 3′,5′- monophosphate-dependent mechanism. Endocrinology. 112(4):1983;1233-1239.
46. Lundberg P., Lie A., Bjurholm A., Lehenkari P.P., Horton M.A., Lerner U.H.et al. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone. 27(6):2000;803-810.
47. Lundberg P., Boström I., Mukohyama H., Bjurholm A., Smans K., Lerner U.H. Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules. Regul. Pept. 85(1):1999;47-58.
48. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M.et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109(7):2002;915-921.
49. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L.et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 111(3):2002;305-317.
50. Sherman B.E., Chole R.A. In vivo effects of surgical sympathectomy on intramembranous bone resorption. Am. J. Otol. 17(2):1996;343-346.
51. Hill E.L., Turner R., Elde R. Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience. 44(3):1991;747-755.
52. Cherruau M., Facchinetti P., Baroukh B., Saffar J.L. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone. 25(5):1999;545-551.
53. Bjurholm A., Kreicbergs A., Schultzberg M., Lerner U.H. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 7(9):1992;1011-1019.
54. Bjurholm A., Kreicbergs A., Schultzberg M., Lerner U.H. Parathyroid hormone and noradrenaline-induced enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line (UMR 106) is inhibited by neuropeptide Y. Acta Physiol. Scand. 134(3):1988;451-452.